Toll-like receptors in cardiovascular diseases

Cardiovascular Research

Volumn 60, Issue 1, 2003, Pages 58-67

  De Kleijn, Dominique ^a,b   Pasterkamp, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Arteries; Atherosclerosis; Immunology; Infection Inflammation; Receptors

Indexed keywords

BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; CYTOKINE; MEMBRANE PROTEIN; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, RAT;

ATHEROSCLEROSIS; BIOACCUMULATION; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CORRELATION ANALYSIS; CROSS TOLERANCE; DENDRITIC CELL; DISEASE ASSOCIATION; ENDOTHELIUM CELL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FIBROBLAST; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INFLAMMATORY CELL; INTIMA; KNOCKOUT MOUSE; MACROPHAGE; MOLECULAR RECOGNITION; MUSCLE CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; REVIEW; TISSUE DISTRIBUTION; TREATMENT INDICATION; ANIMAL; ANIMAL MODEL; ARTERIOSCLEROSIS; GENETICS; HEART MUSCLE CELL; IMMUNOLOGY; IMMUNOTHERAPY; INFECTION; LYMPHOID TISSUE; METABOLISM; MOUSE; RAT; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CYTOKINES; DENDRITIC CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOTHERAPY; INFECTION; LYMPHOID TISSUE; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MODELS, ANIMAL; MYOCYTES, CARDIAC; RATS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 0642312183     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00348-1     Document Type: Review

References (98)

1. George J., Afek A., Gilburd B., et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low density lipoprotein suppresses early atherogenesis. Atherosclerosis. 138:1998;147-152.
2. Zhou X., Caligiuri G., Hamsten A., et al. LDL immunization induces T cell dependent antibody formation and protection against atherosclerosis. Arterioscl Thormb Vasc Biol. 21:2001;108-114.
3. Maron R., Sukhova G., Faria A., et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low density lipoprotein receptor-deficient mice. Circulation. 106:2002;1708-1715.
4. Zhou X., Nicoletti A., Elhage R., et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 102:2000;2919-2922.
5. Muzio M., Natoli G., Saccani S., Levrero M., Mantovani A. The human toll signaling pathway: divergence of nuclear factor kB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med. 187:1998;2097-2101.
6. Faure E., Equils O., Sieling P.A., Thomas L., Zhang F.X., Kirschning C.J., Polentarutti N., Muzio M., Arditi M. Bacterial lipopolysaccharide activates NF kB through toll like receptor 4 in cultured human dermal endothelial cells: differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 275:2000;11058-11063.
7. Dirks S.H., van Deventer S.J.H., Peppelenbosch M.P. Lipopolysaccharide recognition, internalisation, signaling and other cellular effects. J Endotoxin Res. 7:2002;335-348.
8. Curtiss L.K., Kubo N., Schiller N.K., Boisvert W.A. Participation of innate and acquired immunity in atherosclerosis. Immunol Res. 21:2000;167-176.
9. Lusis A.J. Atherosclerosis. Nature. 407:2000;233-241.
10. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 21:2001;1876-1890.
11. Janeway C.A. Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 20:2002;197-216.
12. Yamamoto T., Ebe Y., Hasegawa G., Kataoka M., Yamamoto S., Naito M. Expression of scavenger receptor class A and CD14 in lipopolysaccharide-induced lung injury. Pathol Int. 49:1999;983-992.
13. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:1997;292-296.
14. Lien E., Ingalls R.R. Toll like receptors. Crit Care Med. 30:(suppl):2002;S1-S11.
15. Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 388:1997;394-397.
16. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tlr4 gene. Science. 282:1998;2085-2088.
17. Qureshi S.T., Lariviere L., Leveque G., et al. Endotoxin tolerant mice have mutations in Toll Like receptor 4 (Tlr4). J Exp Med. 189:1999;615-625.
18. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 105:(10):2002;1158-1161.
19. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., Luthringer D., Xu X.P., Rajavashisth T.B., Yano J., Kaul S., Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 104:(25):2001;3103-3108.
20. Wyllie D.H., Kiss-Toth E., Visintin A., Smith S.C., Boussouf S., Segal D.M., Duff G.W., Dower S.K. Evidence for an accessory protein function for Toll like receptor 1 in anti bacterial responses. J Immunol. 165:2000;7125-7132.
21. Ohashi K., Burkart V., Flohe S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 164:2000;558-561.
22. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., Chow J.C., Strauss J.F. 3rd. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 276:2001;10229-10233.
23. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., Simon J.C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 195:2002;99-111.
24. Muzio M., Polentarutti N., Bosisio D., Manoj Kunar P.P., Mantovani A. Toll like receptor family and signaling pathway. Biochem Soc Trans. 28:2000;563-566.
25. Hemmi H., Takeuchi O., Kawai T., et al. A toll like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
26. Guha M., Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 13:2001;85-94.
27. Wright S.D. Toll: a new piece in the puzzle of innate immunity. J Exp Med. 189:1999;605-609.
28. Xu Z., Dziarski R., Wang Q., Swartz K., Sakamoto K.M., Gupta D. Bacterial peptidoglycan-induced tnf-alpha transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kappaB. J Immunol. 167:(12):2001;6975-6982.
29. Yoshimura A., Lien E., Ingalls R.R., Tuomanen E., Dziarski R., Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol. 163:(1):1999;1-5.
30. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., Takeda K., Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 11:(4):1999;443-451.
31. Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B., Bassetti M., Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature. 401:(6755):1999;811-815.
32. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., Schroeder L., Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA. 97:(25):2000;13766-13771.
33. Hajjar A.M., O'Mahony D.S., Ozinsky A., Underhill D.M., Aderem A., Klebanoff S.J., Wilson C.B. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol. 166:(1):2001;15-19.
34. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 249:(4975):1990;1431-1433.
35. Kirkland T.N., Finley F., Leturcq D., Moriarty A., Lee J.D., Ulevitch R.J., Tobias P.S. Analysis of lipopolysaccharide binding by CD14. J Biol Chem. 268:(33):1993;24818-24823.
36. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 189:(11):1999;1777-1782.
37. da Silva Correia J., Soldau K., Christen U., Tobias P.S., Ulevitch R.J. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem. 276:(24):2001;21129-21135.
38. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 1:(2):2001;135-145.
39. Frantz S., Kobzik L., Kim Y.D., Fukazawa R., Medzhitov R., Lee R.T., Kelly R.A. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 104:(3):1999;271-280.
40. Vink A., Schoneveld A.H., van der Meer J.J., van Middelaar B.J., Sluijter J.P., Smeets M.B., Quax P.H., Lim S.K., Borst C., Pasterkamp G., de Kleijn D.P. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation. 106:(15):2002;1985-1990.
41. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., Luthringer D., Xu X.P., Rajavashisth T.B., Yano J., Kaul S., Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 104:(25):2001;3103-3108.
42. Hoshino K., Kaisho T., Iwabe T., Takeuchi O., Akira S. Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation. Int Immunol. 14:(10):2002;1225-1231.
43. Knuefermann P., Nemoto S., Misra A., Nozaki N., Defreitas G., Goyert S.M., Carabello B.A., Mann D.L., Vallejo J.G. CD14-deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation. 106:2002;2608-2615.
44. Nemoto S., Vallejo J.G., Knuefermann P., Misra A., Defreitas G., Carabello B.A., Mann D.L. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Physiol Heart Circ Physiol. 282:2002;H2316-2323.
45. Faure E., Thomas L., Xu H., Medvedev A., Equils O., Arditi M. Bacterial lipopolysaccharide and IFN-γ induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-κB activation. J Immunol. 166:2001;2018-2024.
46. Wang P.L., Oido-Mori M., Fujii T., Kowashi Y., Kikuchi M., Suetsugu Y., Tanaka J., Azuma Y., Shinohara M., Ohura K. Heterogeneous expression of Toll-like receptor 4 and downregulation of Toll-like receptor 4 expression on human gingival fibroblasts by Porphyromonas gingivalis lipopolysaccharide. Biochem Biophys Res Commun. 288:2001;863-867.
47. Nomura F., Akashi S., Sakao Y., Sato S., Kawai T., Matsumoto M., Nakanishi K., Kimoto M., Miyake K., Takeda K., Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol. 164:2000;3476-3479.
48. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T., Endres S., Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 168:2002;4531-4537.
49. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 194:2001;863-869.
50. Bobryshev Y.V., Ikezawa T., Watanabe T. Formation of Birbeck granule-like structures in vascular dendritic cells in human atherosclerotic aorta. Lag-antibody to epidermal Langerhans cells recognizes cells in the aortic wall. Atherosclerosis. 133:1997;193-202.
51. Waltner-Romen M., Falkensammer G., Rabl W., Wick G. A previously unrecognized site of local accumulation of mononuclear cells: the vascular-associated lymphoid tissue. J Histochem Cytochem. 46:1998;1347-1350.
52. Millonig G., Niederegger H., Rabl W., Hochleitner B.W., Hoefer D., Romani N., Wick G. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol. 21:2001;503-508.
53. Wick G., Romen M., Amberger A., Metzler B., Mayr M., Falkensammer G., Xu Q. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J. 11:1997;1199-1207.
54. Lord R.S., Bobryshev Y.V. Clustering of dendritic cells in athero-prone areas of the aorta. Atherosclerosis. 146:1999;197-198.
55. Bobryshev Y.V., Lord R.S. Vascular-associated lymphoid tissue (VALT) involvement in aortic aneurysm. Atherosclerosis. 154:2001;15-21.
56. Gregory A.K., Yin N.X., Capella J., Xia S., Newman K.M., Tilson M.D. Features of autoimmunity in the abdominal aortic aneurysm. Arch Surg. 131:1996;85-88.
57. Houtkamp M.A., de Boer O.J., van der Loos C.M., van der Wal A.C., Becker A.E. Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J Pathol. 193:2001;263-269.
58. Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med. 340:1999;115-126.
59. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 91:2002;281-291.
60. Fuster V., Badimon L., Badimon J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. New Engl J Med. 326:1992;242-250. See also pp. 310-8.
61. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W. Jr., Rosenfeld M.E., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 15:1995;1512-1531.
62. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:(6):1994;2493-2503.
63. Shah P.K., Falk E., Badimon J.J., Fernandez O.A., Mailhac A., Villareal L.G., Fallon J.T., Regnstrom J., Fuster V. Human monocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix degrading metalloproteinases and implications for plaque rupture. Circulation. 92:(6):1995;1565-1569.
64. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 1589:2002;1-13.
65. Prescott M.F., McBride C.K., Court M. Development of intimal lesions after leukocyte migration into the vascular wall. Am J Pathol. 135:1989;835-846.
66. Paigen B., Holmes P.A., Novak E.K., Swank R.T. Analysis of atherosclerosis susceptibility in mice with genetic defects in platelet function. Arteriosclerosis. 10:1990;648-652.
67. Nishina P.M., Wang J., Toyofuku W., Kuypers F.A., Ishida B.Y., Paigen B. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids. 28:1993;599-605.
68. Grimsditch D.C., Penfold S., Latcham J., Vidgeon-Hart M., Groot P.H., Benson G.M. C3H apoE(-/-) mice have less atherosclerosis than C57BL apoE(-/-) mice despite having a more atherogenic serum lipid profile. Atherosclerosis. 151:2000;389-397.
69. Wright S.D., Burton C., Hernandez M., Hassing H., Montenegro J., Mundt S., Patel S., Card D.J., Hermanowski-Vosatka A., Bergstrom J.D., Sparrow C.P., Detmers P.A., Chao Y.S. Infectious agents are not necessary for murine atherogenesis. J Exp Med. 191:2000;1437-1442.
70. Shi W., Wang X., Tangchitpiyanond K., Wong J., Shi Y., Lusis A.J. Atherosclerosis in C3H/HeJ mice reconstituted with apolipoprotein E-null bone marrow. Arterioscler Thromb Vasc Biol. 22:2002;650-655.
71. Kaisho T., Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol. 22:2001;78-83.
72. Stary H.C., Blankenhorn D.H., Chandler A.B., Glagov S., Insull W. Jr., Richardson M., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 12:1992;120-134.
73. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., Willeit J., Schwartz D.A. Toll-like receptor 4 polymorphisms and atherogenesis. New Engl J Med. 347:2002;185-192.
74. Watari M., Watari H., Nachamkin I., Strauss J.F. Lipopolysaccharide induces expression of genes encoding pro-inflammatory cytokines and the elastin-degrading enzyme, cathepsin S, in human cervical smooth-muscle cells. J Soc Gynecol Invest. 7:2000;190-198.
75. Walle T.K., Vartio T., Helve T., Virtanen I., Kurki P. Cellular fibronectin in rheumatoid synovium and synovial fluid: a possible factor contributing to lymphocytic infiltration. Scand J Immunol. 31:1990;535-540.
76. Matsui S., Takahashi T., Oyanagi Y., Takahashi S., Boku S., Takahashi K., Furukawa K., Arai F., Asakura H. Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma. J Hepatol. 27:(5):1997;843-853.
77. Cornford P.A., Dodson A.R., Parsons K.F., Desmond A.D., Woolfenden A., Fordham M., Neoptolemos J.P., Ke Y., Foster C.S. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60:2000;7099-7105.
78. Laman J.D., Schoneveld A.H., Moll F.L., van Meurs M., Pasterkamp G. Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am J Cardiol. 90:2002;119-123.
79. Smith R.S., Smith T.J., Blieden T.M., Phipps R.P. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 151:1997;317-322.
80. de Kleijn D.P., Smeets M.B., Kemmeren P.P., Lim S.K., Van Middelaar B.J., Velema E., Schoneveld A., Pasterkamp G., Borst C. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J. 16:2002;1123-1125.
81. Shi Y., O'Brien J.E., Fard A., Mannion J.D., Wang D., Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 94:1996;1655-1664.
82. Li G., Chen S.J., Oparil S., Chen Y.F., Thompson J.A. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 101:2000;1362-1365.
83. Laine P., Kaartinen M., Penttila A., Panula P., Paavonen T., Kovanen P.T. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation. 99:1999;361-369.
84. Vink A., Pasterkamp G., Poppen M., Schoneveld A.H., de Kleijn D.P., Roholl P.J., Fontijn J., Plomp S., Borst C. The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae. Atherosclerosis. 157:2001;117-122.
85. Jacinto R., Hartung T., McCall C., Li L. Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor-associated kinase. J Immunol. 168:2002;6136-6141.
86. Medvedev A.E., Henneke P., Schromm A., Lien E., Ingalls R., Fenton M.J., Golenbock D.T., Vogel S.N. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol. 167:2001;2257-2267.
87. Lehner M.D., Morath S., Michelsen K.S., Schumann R.R., Hartung T. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol. 166:2001;5161-5167.
88. Lemaire L.C., van der Poll T., van Lanschot J.J., Endert E., Buurman W.A., van Deventer S.J., Gouma D.J. Minimally invasive surgery induces endotoxin-tolerance in the absence of detectable endotoxemia. J Clin Immunol. 18:1998;414-420.
89. Wurfel M.M., Monks B.G., Ingalls R.R., Dedrick R.L., Delude R., Zhou D., Lamping N., Schumann R.R., Thieringer R., Fenton M.J., Wright S.D., Golenbock D. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact. J Exp Med. 186:1997;2051-2056.
90. Zweigner J., Gramm H.J., Singer O.C., Wegscheider K., Schumann R.R. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood. 98:2001;3800-3808.
91. Schimke J., Mathison J., Morgiewicz J., Ulevitch R.J. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA. 95:1998;13875-13880.
92. Iwami K.I., Matsuguchi T., Masuda A., Kikuchi T., Musikacharoen T., Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol. 165:2000;6682-6686.
93. de Korte C.L., Sierevogel M.J., Mastik F., Strijder C., Schaar J.A., Velema E., Pasterkamp G., Serruys P.W., van der Steen A.F. Identification of atherosclerotic plaque components with intravascular ultrasound elastography in vivo: a Yucatan pig study. Circulation. 105:(14):2002;1627-1630.
94. Stefanadis C., Toutouzas K., Tsiamis E., Stratos C., Vavuranakis M., Kallikazaros I., Panagiotakos D., Toutouzas P. Increased local temperature in human coronary atherosclerotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. J Am Coll Cardiol. 37:(5):2001;1277-1283.
95. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 18:(7):1997;335-343.
96. Weiner H.L. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest. 106:(8):2000;935-937.
97. Xu Q., Wick G. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol Med Today. 2:1996;372-379.
98. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 3:2002;196-200.